| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JNC.12296 |
| P8608 | Fatcat ID | release_xrlnzkhbljhjxi5qlwn4llndue |
| P698 | PubMed publication ID | 23651058 |
| P5875 | ResearchGate publication ID | 236652416 |
| P50 | author | André Luiz Sena Guimarães | Q42705054 |
| Marco Antonio Maximo Prado | Q44583422 | ||
| Vania F Prado | Q45827795 | ||
| Vilma R Martins | Q45827808 | ||
| Valeriy Ostapchenko | Q62571142 | ||
| P2093 | author name string | Jue Fan | |
| Monica Guzman | |||
| Flavio H Beraldo | |||
| Sanju Mishra | |||
| P2860 | cites work | Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers | Q22251089 |
| beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology | Q22253223 | ||
| Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection | Q24534939 | ||
| Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease | Q24620534 | ||
| Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein | Q24630045 | ||
| Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases | Q24633202 | ||
| Prions | Q24633319 | ||
| Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake | Q24656613 | ||
| Alzheimer's disease and insulin resistance: translating basic science into clinical applications | Q26996487 | ||
| Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase | Q28188098 | ||
| Physiology of the prion protein | Q28275220 | ||
| Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers | Q28308082 | ||
| Regulation of NMDA receptor trafficking by amyloid-beta | Q28506085 | ||
| Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein | Q28771710 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| A beta oligomers - a decade of discovery | Q29615152 | ||
| Memory impairment in transgenic Alzheimer mice requires cellular prion protein | Q30032301 | ||
| Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission | Q30472919 | ||
| Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5 | Q30500964 | ||
| Cleavage of the amino terminus of the prion protein by reactive oxygen species. | Q31520300 | ||
| Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents | Q33193869 | ||
| Interplay among platelet-activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival. | Q33204967 | ||
| Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. | Q33206011 | ||
| Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta | Q33218208 | ||
| Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse | Q33718694 | ||
| Endogenous proteolytic cleavage of disease-associated prion protein to produce C2 fragments is strongly cell- and tissue-dependent | Q33795953 | ||
| Novel strains of mice deficient for the vesicular acetylcholine transporter: insights on transcriptional regulation and control of locomotor behavior | Q33851514 | ||
| Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues | Q34074414 | ||
| Prion protein in Alzheimer's pathogenesis: a hot and controversial issue | Q34130611 | ||
| Probing the biology of Alzheimer's disease in mice | Q34206962 | ||
| Prion protein and Abeta-related synaptic toxicity impairment | Q34233877 | ||
| Cellular prion protein: on the road for functions | Q34536249 | ||
| Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets | Q34784378 | ||
| Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites | Q35166748 | ||
| The distinct role of mGlu1 receptors in post-ischemic neuronal death | Q35216446 | ||
| The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease | Q35327219 | ||
| A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. | Q35626193 | ||
| α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death | Q35763065 | ||
| An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers | Q35858008 | ||
| Cells release prions in association with exosomes | Q36448448 | ||
| Amyloid beta peptides and glutamatergic synaptic dysregulation | Q37021970 | ||
| Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta} | Q37253971 | ||
| Endocytosis of prion protein is required for ERK1/2 signaling induced by stress-inducible protein 1. | Q37335792 | ||
| Protein aggregation as a paradigm of aging | Q37520024 | ||
| α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential | Q37806286 | ||
| mGluRs modulate strength and timing of excitatory transmission in hippocampal area CA3. | Q37874147 | ||
| Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo | Q39389999 | ||
| Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein | Q39831418 | ||
| alpha-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts | Q39908845 | ||
| The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity | Q40360129 | ||
| A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44 | Q40361195 | ||
| Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells | Q40438114 | ||
| Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. | Q40572421 | ||
| Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice | Q41230899 | ||
| The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo | Q42151993 | ||
| The prion protein as a receptor for amyloid-beta. | Q42692268 | ||
| N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers | Q42857361 | ||
| Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities | Q45310539 | ||
| Amyloid-beta oligomers increase the localization of prion protein at the cell surface | Q45827724 | ||
| Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes | Q46540225 | ||
| Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. | Q46843638 | ||
| Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. | Q48306292 | ||
| PrP(C) homodimerization stimulates the production of PrPC cleaved fragments PrPN1 and PrPC1. | Q48369828 | ||
| Truncated forms of the human prion protein in normal brain and in prion diseases | Q48807964 | ||
| Transgenic mice as a model of pre-clinical Alzheimer's disease. | Q51027885 | ||
| Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin γ1 chain. | Q51035911 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prion protein family | Q24724413 |
| P304 | page(s) | 415-425 | |
| P577 | publication date | 2013-05-27 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Increased prion protein processing and expression of metabotropic glutamate receptor 1 in a mouse model of Alzheimer's disease. | |
| P478 | volume | 127 |
| Q35546911 | A genome wide association study links glutamate receptor pathway to sporadic Creutzfeldt-Jakob disease risk |
| Q51531026 | Ambient Glutamate Promotes Paroxysmal Hyperactivity in Cortical Pyramidal Neurons at Amyloid Plaques via Presynaptic mGluR1 Receptors. |
| Q89486165 | Amyloid Fibril-Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses |
| Q34391341 | Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity |
| Q61818017 | Detection of Active Caspase-3 in Mouse Models of Stroke and Alzheimer's Disease with a Novel Dual Positron Emission Tomography/Fluorescent Tracer [Ga]Ga-TC3-OGDOTA |
| Q38808517 | Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity. |
| Q57156403 | Fragile X and APP: a Decade in Review, a Vision for the Future |
| Q47099606 | Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity. |
| Q30580280 | Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease |
| Q38193084 | Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders |
| Q49957320 | Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases |
| Q54224345 | Prions, prionoids and protein misfolding disorders. |
| Q40562510 | Regulation of Amyloid β Oligomer Binding to Neurons and Neurotoxicity by the Prion Protein-mGluR5 Complex |
| Q38802640 | Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future |
| Q38171006 | Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases. |
| Q38186552 | The GPI-anchoring of PrP: implications in sorting and pathogenesis. |
| Q48106243 | The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment. |
| Q38623320 | The pathogenesis of soluble PrP fragments containing Aβ binding sites |
| Q44331418 | The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicity. |
| Q35137829 | The sheddase ADAM10 is a potent modulator of prion disease. |
| Q64084664 | Unchanged type 1 metabotropic glutamate receptor availability in patients with Alzheimer's disease: A study using C-ITMM positron emission tomography |
Search more.